INTRODUCING THE EXSIGHT VENTURES SYNDICATE ON ANGELLIST

THE EXSIGHT VENTURES TEAM IS ENTHUSIASTICALLY ANNOUNCING THE LAUNCH OF EXSIGHT VENTURES SYNDICATE ON ANGELLIST

AngelList is a platform site that enables accredited investors to invest in companies and funds. Syndicates “are single-deal VC funds created to invest in a specific startup.” AngelList Syndicates allow investors “to invest deal-by-deal in specific companies.” AngelList provides a digital platform that will enable both ExSight Ventures and these companies access to additional investors outside of our existing networks. The platform delivers an efficient solution for us to offer and administer co-investment opportunities.
 
Our investment strategy targets the most promising early-stage ophthalmology companies. These prospective investments include innovative companies that span sectors including therapeutics, diagnostics, and devices. The financings these companies are seeking to raise are frequently more than our current investment capabilities permit. We believe we have found a solution that will help us scale our investment capabilities and strengthen our investing abilities.
 
The ExSight Ventures Syndicate will provide our existing investors and other accredited investors access to the types of investments that comprise our current portfolio. Where and when possible, we will use AngelList Syndicates to amplify the firm’s capabilities. Not every opportunity will qualify for the Syndicate nor will it always be possible to obtain an allocation, particularly in deals where ExSight Ventures does not lead. Our AngelList Syndicate will allow our “backers” to help us fund the most innovative companies in vision care. The AngelList platform will help us in our mission to preserve and restore vision. We have built a very robust pipeline of investment opportunities and are eager to maximize our participation in those opportunities through AngelList Syndicates. 

Back syndicate here

Previous
Previous

ELECTRIFYING VISION: ANNOUNCING OUR INVESTMENT IN 2C TECH

Next
Next

LENSGEN IS THE TALK OF THE TOWN @ ASCRS 2019